Effects of Sindilizumab Combined with TP Chemotherapy on Levels of PD-1,PD-L1 and Tumor Markers in Patients with Advanced Esophageal Cancer
WANG Xingwang
ZHANG Bingyan
FENG Juanjuan
LI Bo
JIN Ziqi
Abstract：Objective To investigate the effect of sindelizumab combined with paclitaxel-cisplatin(TP)chemotherapy in advanced esophageal cancer.Methods 80 patients with advanced esophageal cancer admitted to Hebi People's Hospital from June 2022 to December 2023 were divided randomly into control group(only received TP chemotherapy)and observation group(received Sindilumab combined with TP chemotherapy on the basis of control group),with 40 cases in each.The clinical efficacy,programmed death-1(PD-1)and programmed death-ligand 1(PD-L1)in blood levels,serum tumor marker levels,incidence of adverse reactions and 1 a survival rate were compared between the two groups.Results After treatment,the levels of PD-1,PD-L1 and tumor markers in both groups decreased,and the levels were lower in observation group than those in control group(P＜0.05).After treatment,the total effective rate of the observation group was 87.5%,and the 1-year survival rate was 32.50%,which were significantly higher than 67.50%and 12.50%ofthe control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P＞0.05).The survival curves of the two groups were drawn by Kaplan-Meier method.The 1-year survival rate of the observation group was higher than that of the control group,and the difference was statistically significant(Log-rank χ2=6.901,P=0.009).Conclusion Sindilizumab combined with TP chemotherapy is effective in the treatment of advanced esophageal cancer patients,which can effectively reduce the levels of PD-1,PD-L1 and tumor markers,and significantly improve the 1-year survival rate,with certain safety.
Keywords：sindilimabTP chemotherapyesophageal cancerprogrammed death receptor 1programmed death receptor ligand 1
Publication Date：2026-03-25
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：5( 28-32 )